The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens
Abstract
Daptomycin is a novel cyclic lipopeptide antibiotic that provides rapid bactericidal activity against gram-positive pathogens in vitro, including methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, vancomycin-resistant S. aureus, penicillin-resistant Streptococcus pneumoniae, and ampicillin- and vancomycin-resistant enterococci. The United States Food and Drug Administration recently approved daptomycin for treatment of complicated skin and skin-structure infections. Its efficacy in the treatment of more-serious infections (e.g., staphylococcal bacteremia) is under investigation. As an intravenous agent that is administered once per day, it offers a convenient regimen for therapy that is continued after discharge, with a side effect profile that appears minimal and manageable. Spontaneous acquisition of resistance in vitro is rare, and hopefully this characteristic will extrapolate into the clinical setting. The rapid bactericidal activity, low potential for resistance, and promising safety profile associated with this agent will make it a useful addition to our growing armamentarium of antibiotics active against gram-positive pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095
Rybak, M. J., Hershberger, E., Moldovan, T., & Grucz, R. G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1062-1066.2000 · Cited by 362
Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Development of daptomycin for Gram-positive infections
Tally, F. P., & DeBruin, M. F. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.4.523 · Cited by 321
Resistance Studies with Daptomycin
Silverman, J. A., Oliver, N., Andrew, T., & Li, T. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1799-1802.2001 · Cited by 234
Daptomycin: a novel agent for Gram-positive infections
Tally, F. P., Zeckel, M., Wasilewski, M. M., Carini, C., Berman, C. L., Drusano, G. L., & Oleson JR, F. B. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.8.1223 · Cited by 205
Once-Daily Dosing in Dogs Optimizes Daptomycin Safety
Oleson, F. B., Berman, C. L., Kirkpatrick, J. B., Regan, K. S., Lai, J.-J., & Tally, F. P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.2948-2953.2000 · Cited by 196
Quinupristin‐Dalfopristin and Linezolid: Evidence and Opinion
Eliopoulos, G. M. (2003) · Clinical Infectious Diseases · doi:10.1086/367662 · Cited by 169
Novel antibacterial agents for the treatment of serious Gram-positive infections
Abbanat, D., Macielag, M. J., & Bush, K. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.379 · Cited by 134
FUCHS, P. C., Barry, A. L., & Brown, S. D. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(00)00164-4 · Cited by 122
Cited by
Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department
Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., & Talan, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055356 · Cited by 2,285
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationInfections associated with orthopedic implants
Trampuz, A., & Widmer, A. F. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000235161.85925.e8 · Cited by 542
Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J. (2005) · The Journal of Infectious Diseases · doi:10.1086/430352 · Cited by 541
Metadata
- Authors
- Carpenter, C. F., & Chambers, H. F.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-04
- Volume
- 38
- Issue
- 7
- Pages
- 994-1000
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2023046401
- Cited by
- 358
- References
- 16
- FWCI
- 22.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens. https://app.cochat.ai/papers/10.1086/383472
- The paper
- Carpenter, C. F., & Chambers, H. F. (2004). Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens. Clinical Infectious Diseases. https://doi.org/10.1086/383472
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
